Private equity firm ChrysCapital has successfully completed its acquisition of a 70.68% stake in listed pharmaceutical trading and distribution company Novartis India Ltd (NIL), marking the firm's first majority-controlled investment in the Indian pharmaceutical sector. The transaction, valued at approximately ₹1,446 crore, was completed with the appointment of Dr. Vikas Gupta as the new Managing Director and Chief Executive Officer. The deal, which was first announced in February 2026, was completed with the exit of erstwhile promoter Novartis AG, which sold 1,74,50,680 equity shares via an off-market transfer dated February 19, 2026. The acquiring consortium comprises WaveRise Investments Limited (56.45%), ChrysCapital Fund X (10.32%), and Two Infinity Partners (3.91%), with ChrysCapital X, LLC and OceanEdge Investments Limited acting as Persons Acting in Concert. As per Business Standard, this acquisition is among the largest recent private equity investments in India's pharmaceutical sector and follows Novartis AG's decision to divest its controlling stake in the listed Indian subsidiary as part of its global portfolio strategy.
As part of the transaction, NIL has inducted Ramesh Ramadurai, Suchita Sharma, and Shashank Sinha to the board as independent directors, with Ramadurai serving as Chairperson of the Board. According to the company statement, the acquisition will result in NIL adopting a new name and corporate identity to mark its separation from previous owners and the beginning of a new era. Gupta stated that with ChrysCapital's backing, the company has the resources and focus to grow its portfolio with purpose and reach more patients, building on its legacy of scientific rigour and physician trust. Kshitij Sheth, Managing Director at ChrysCapital Advisors, highlighted the importance of the new management team, stating "A strong management team is central to any successful organisation, and NIL is fortunate to have Dr. Vikas Gupta at the helm." The new management team includes several senior appointments aimed at stabilizing operations and driving growth, with Bhagwat Singh Deora as Chief Financial Officer, Jason D'Souza as President – M&A & IR, Rahul Vijayvargiya as Chief Human Resource Officer, Masud Shaikh as Chief Supply Chain Officer, and Sumeet Rajput as President – Business Operations, all effective July 29, 2026.
Dr. Vikas Gupta, who most recently served as CEO of Alkem Laboratories, one of India's largest pharmaceutical companies, brings more than two decades of industry experience to his new role. A medical graduate from the University College of Medical Sciences, Delhi University, he has worked across a broad spectrum of therapeutic segments, including acute care, chronic diseases, metabolic disorders and respiratory therapies. He is also known for leading business transformation initiatives and driving growth across multiple markets and geographies. According to the company statement, the acquisition will result in NIL adopting a new name and corporate identity to mark its separation from previous owners and the beginning of a new era. Gupta stated that with ChrysCapital's backing, the company has the resources and focus to grow its portfolio with purpose and reach more patients, building on its legacy of scientific rigour and physician trust.
To secure its product portfolio post-acquisition, Novartis India executed three key agreements with Novartis entities on July 29, 2026. The most significant is the Tegrital Brand License Deed, which grants the company an exclusive, irrevocable, royalty-free, and non-assignable license to use the 'Tegrital' trademark in India. Under this deed, Novartis AG must automatically assign the trademark to the company at no additional cost, provided there is no material breach by the company, ensuring uninterrupted manufacturing, marketing, and sales of the Tegrital range of pharmaceutical products. Additionally, the company signed a Distribution Agreement with Novartis Pharma Services AG, appointing it as the exclusive distributor to import and sell certain pharmaceutical products in India. This agreement has an initial term of five years, extendable by another five years subject to mutual consent, with supply prices fixed for the first year and subsequent pricing determined by a mechanism outlined in the contract. A separate Trademark Assignment and License Deed transferred ownership of other key brands, including Voveran, Macalvit, and Citromacalvit, to the company on a royalty-free basis.
While the acquisition affects NIL, Novartis will continue its presence in India through Novartis Healthcare Pvt. Ltd (NHPL), a wholly owned subsidiary that includes the commercial arm, Novartis Corporate Centre in Hyderabad, and research and development teams conducting clinical trials at more than 300 sites across the country. As reported by The Economic Times, the transfer of Novartis AG's shareholding in NIL will not impact NHPL's operations, ensuring continuity in Novartis's Indian operations. ChrysCapital plans to leverage its healthcare investment experience and operating network to build a domestic branded formulation growth platform around the company rather than operate it as a carve-out asset. The deal hands ChrysCapital control of a pharmaceutical business with a decades-long presence in India and a portfolio of established brands including Voveran, Calcium Sandoz, and Tegrital, spanning therapies such as pain management, calcium supplementation, gynaecology, neurosciences and transplant immunology. At 11.02 am, Novartis India share was trading at ₹1,650 on the National Stock Exchange, up 3% from the previous close, indicating positive market sentiment toward the strategic transformation. ChrysCapital said the company would adopt a new name and corporate identity as it separates from its former parent and seeks to build a leading branded generics platform in India, with the company well positioned for long-term value creation under its new leadership.
Kotak acted as the exclusive financial advisor for the transaction, while Ernst & Young advised Novartis AG on financial and tax due diligence. For ChrysCapital, Alvarez & Marsal, Dhruva Advisors and Price Waterhouse & Co. served as financial and tax advisors. The transaction brings one of the country's longstanding pharmaceutical businesses under dedicated private equity ownership with ambitions to build a leading branded-generics platform. The Board also reconstituted its Risk Management Committee and Stakeholders Relationship Committee to align with the new director lineup, with Shashank Sinha chairing the Risk Management Committee and Ashok Bhatia leading the Stakeholders Relationship Committee. For the legal aspects, Freshfields and AZB & Partners served as legal advisers to Novartis AG, while Shardul Amarchand Mangaldas & Co advised ChrysCapital on the legal aspects of the deal. Historical stock returns show Novartis shares have gained 60.32% over one year and 69.29% over five years, indicating positive market sentiment toward the strategic transformation.
